- 全部删除
您的购物车当前为空
Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体,具有显著的抗肿瘤活性,通过与 PD-1 结合从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用,进而恢复内源性抗肿瘤 T 细胞反应。Sintilimab 联合其他化合物来治疗经典霍奇金淋巴瘤、非小细胞肺癌和食管癌。

为众多的药物研发团队赋能,
让新药发现更简单!
Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体,具有显著的抗肿瘤活性,通过与 PD-1 结合从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用,进而恢复内源性抗肿瘤 T 细胞反应。Sintilimab 联合其他化合物来治疗经典霍奇金淋巴瘤、非小细胞肺癌和食管癌。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,570 | In stock | |
| 5 mg | ¥ 4,100 | In stock | |
| 10 mg | ¥ 6,990 | In stock | |
| 25 mg | ¥ 10,300 | In stock | |
| 50 mg | ¥ 13,900 | In stock |
Sintilimab 相关产品
| 产品描述 | Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer. |
| 别名 | Sintilimab (anti-PD-1), IBI308 |
| 分子量 | 144.04 kDa |
| CAS No. | 2072873-06-2 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容